PRODUCT TYPES – Page 9

Cryopreservation failure during tech transfer: patient safety impact and disposition

Identifying signs of cryopreservation failure is crucial for timely intervention. Symptoms may present themselves both on the manufacturing floor or in the laboratory as follows:Click to read the full article.

API batch-to-batch variability trend (OOT) after equipment maintenance intervention: regulatory impact assessment and change control remediation plan

The identification of symptoms or signals indicating batch variability is the first step in addressing potential quality issues. Common signals may include:Click to read the full article.

Cell viability failure during scale-up: inspection-ready investigation package

Cells may exhibit several symptoms when viability issues arise during scale-up, including significant decreases in cell density, abnormal morphology, or loss of function. Key signals to monitor include:Click to read…

API assay drift during stability pull at 6/12 months: how to justify reprocessing vs rejection to FDA/EMA inspectors

Identifying the symptoms of API assay drift is crucial for effective investigation and decision-making. Common indicators include:Click to read the full article.

Vector potency drift during tech transfer: patient safety impact and disposition

Identifying symptoms or signals of vector potency drift is the first critical step in initiating an investigation. Common symptoms that may indicate a problem include:Click to read the full article.

API starting material traceability gap after drying cycle optimization: risk-based approach to prevent repeat OOS across future API batches

A gap in traceability often becomes evident through various symptoms on the manufacturing floor or within the laboratory setting. Recognizing these signals early can prevent significant setbacks. Key indications of…

Cryopreservation failure during ATMP manufacturing: patient safety impact and disposition

Identifying the symptoms or signals of a cryopreservation failure is the first step in investigation. Common indicators include:Click to read the full article.

API hygroscopicity-driven degradation after raw material supplier change: how to write a defensible deviation narrative for inspections

The initial signs of hygroscopicity-driven degradation may be subtle but can escalate rapidly if not managed accordingly. Healthcare professionals and QC personnel should be vigilant for symptoms such as:Click to…

Vector potency drift during stability testing: inspection-ready investigation package

Identifying symptoms or signals of vector potency drift early is crucial for timely intervention. Symptoms may include:Click to read the full article.

API heavy metals / elemental impurities OOS after cleaning validation requalification: root cause analysis (process vs lab) with CAPA effectiveness checks

Recognizing the first signals of potential contamination can lead to timely investigations and prevent widespread product quality issues. The symptoms associated with OOS heavy metals or elemental impurities include:Click to…

Chain of identity breach during stability testing: patient safety impact and disposition

Identifying symptoms that indicate a potential chain of identity breach during stability testing is vital. Some key signals include:Click to read the full article.

API assay drift after raw material supplier change: data integrity and chromatographic audit trail review steps

Identifying the symptoms of API assay drift is crucial in the early stages of your investigation. Symptoms may manifest in several ways:Click to read the full article.